Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
He, JC; Yao, W; Wang, JM; Schemmer, P; Yang, Y; Liu, Y; Qian, YW; Qi, WP; Zhang, J; Shen, Q; Yang, T.
TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors.
Oncotarget. 2016; 7(46):75441-75456
Doi: 10.18632/oncotarget.12254
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Schemmer Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Histone deacetylases (HDACs) have been implicated in multiple malignant tumors, and HDAC inhibitors (HDACIs) exert anti-cancer effects. However, the expression of HDACs and the anti-tumor mechanism of HDACIs in cholangiocarcinoma (CCA) have not yet been elucidated. In this study, we found that expression of HDACs 2, 3, and 8 were up-regulated in CCA tissues and those patients with high expression of HDAC2 and/or HDAC3 had a worse prognosis. In CCA cells, two HDACIs, trichostatin (TSA) and vorinostat (SAHA), suppressed proliferation and induced apoptosis and G2/M cycle arrest. Microarray analysis revealed that TACC3 mRNA was down-regulated in CCA cells treated with TSA. TACC3 was highly expressed in CCA tissues and predicted a poor prognosis in CCA patients. TACC3 knockdown induced G2/M cycle arrest and suppressed the invasion, metastasis, and proliferation of CCA cells, both in vitro and in vivo. TACC3 overexpression reversed the effects of its knockdown. These findings suggest TACC3 may be a useful prognostic biomarker for CCA and is a potential therapeutic target for HDACIs.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Animals -
- Antineoplastic Agents - pharmacology
- Antineoplastic Agents - therapeutic use
- Cell Line, Tumor -
- Cell Movement - genetics
- Cell Proliferation - genetics
- Cholangiocarcinoma - drug therapy
- Cholangiocarcinoma - genetics
- Cholangiocarcinoma - mortality
- Cholangiocarcinoma - pathology
- Disease Models, Animal -
- Female -
- Gene Expression -
- Gene Expression Profiling -
- Gene Knockdown Techniques -
- Histone Deacetylase 2 - genetics
- Histone Deacetylase 2 - metabolism
- Histone Deacetylase Inhibitors - pharmacology
- Histone Deacetylase Inhibitors - therapeutic use
- Histone Deacetylases - genetics
- Histone Deacetylases - metabolism
- Humans -
- Male -
- Mice -
- Microtubule-Associated Proteins - antagonists & inhibitors
- Microtubule-Associated Proteins - genetics
- Middle Aged -
- Molecular Targeted Therapy -
- Neoplasm Grading -
- Neoplasm Metastasis -
- Neoplasm Staging -
- Prognosis -
- Proportional Hazards Models -
- Xenograft Model Antitumor Assays -
- Find related publications in this database (Keywords)
- histone deacetylase (HDAC)
- HDAC inhibitors (HDACIs)
- microarray
- transforming acidic coiled-coil-containing protein 3 (TACC3)
- cholangiocarcinoma (CCA)